A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients

William J Gradishar*, Gerald Soff, Jiangou Liu, Angela Cisneros, Suzanne French, Alfred W Rademaker, Al B Benson III, Noel Bouck

*Corresponding author for this work

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis. Using an established fixed dosing scheme for the administration of suramin in patients, a pilot study was conducted in patients with progressive, metastatic breast cancer. The primary objective of this trial is to define the effect of suramin on the angiogenic activity in individual patients using in vitro laboratory assays. The secondary objective was to assess the antitumor effect of suramin in a population of metastatic breast cancer patients. No objective tumor responses were observed in any of the 9 patients who received treatment with suramin, however 1 patient did maintain stable disease status. The strength of angiogenic activity present in patient samples was assessed by testing patient plasma in the capillary endothelial cell migration assay. Angiogenic activity followed over time was lowest in patients with the highest suramin concentrations and highest in patients with the lowest suramin concentrations. We conclude that it is feasible to continually monitor the activity of antiangiogenic agents in individual patients without relying on clinical tumor response. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish (US)
Pages (from-to)324-333
Number of pages10
JournalONCOLOGY
Volume58
Issue number4
DOIs
StatePublished - Jan 1 2000

Fingerprint

Suramin
Breast Neoplasms
Neoplasms
Cell Migration Assays
Angiogenesis Inhibitors
Action Potentials
Intercellular Signaling Peptides and Proteins
Endothelial Cells

Keywords

  • Antiangiogenesis
  • Breast cancer
  • Suramin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gradishar, William J ; Soff, Gerald ; Liu, Jiangou ; Cisneros, Angela ; French, Suzanne ; Rademaker, Alfred W ; Benson III, Al B ; Bouck, Noel. / A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. In: ONCOLOGY. 2000 ; Vol. 58, No. 4. pp. 324-333.
@article{a165125815ab4025932ba64880226a8a,
title = "A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients",
abstract = "Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis. Using an established fixed dosing scheme for the administration of suramin in patients, a pilot study was conducted in patients with progressive, metastatic breast cancer. The primary objective of this trial is to define the effect of suramin on the angiogenic activity in individual patients using in vitro laboratory assays. The secondary objective was to assess the antitumor effect of suramin in a population of metastatic breast cancer patients. No objective tumor responses were observed in any of the 9 patients who received treatment with suramin, however 1 patient did maintain stable disease status. The strength of angiogenic activity present in patient samples was assessed by testing patient plasma in the capillary endothelial cell migration assay. Angiogenic activity followed over time was lowest in patients with the highest suramin concentrations and highest in patients with the lowest suramin concentrations. We conclude that it is feasible to continually monitor the activity of antiangiogenic agents in individual patients without relying on clinical tumor response. Copyright (C) 2000 S. Karger AG, Basel.",
keywords = "Antiangiogenesis, Breast cancer, Suramin",
author = "Gradishar, {William J} and Gerald Soff and Jiangou Liu and Angela Cisneros and Suzanne French and Rademaker, {Alfred W} and {Benson III}, {Al B} and Noel Bouck",
year = "2000",
month = "1",
day = "1",
doi = "10.1159/000012120",
language = "English (US)",
volume = "58",
pages = "324--333",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. / Gradishar, William J; Soff, Gerald; Liu, Jiangou; Cisneros, Angela; French, Suzanne; Rademaker, Alfred W; Benson III, Al B; Bouck, Noel.

In: ONCOLOGY, Vol. 58, No. 4, 01.01.2000, p. 324-333.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients

AU - Gradishar, William J

AU - Soff, Gerald

AU - Liu, Jiangou

AU - Cisneros, Angela

AU - French, Suzanne

AU - Rademaker, Alfred W

AU - Benson III, Al B

AU - Bouck, Noel

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis. Using an established fixed dosing scheme for the administration of suramin in patients, a pilot study was conducted in patients with progressive, metastatic breast cancer. The primary objective of this trial is to define the effect of suramin on the angiogenic activity in individual patients using in vitro laboratory assays. The secondary objective was to assess the antitumor effect of suramin in a population of metastatic breast cancer patients. No objective tumor responses were observed in any of the 9 patients who received treatment with suramin, however 1 patient did maintain stable disease status. The strength of angiogenic activity present in patient samples was assessed by testing patient plasma in the capillary endothelial cell migration assay. Angiogenic activity followed over time was lowest in patients with the highest suramin concentrations and highest in patients with the lowest suramin concentrations. We conclude that it is feasible to continually monitor the activity of antiangiogenic agents in individual patients without relying on clinical tumor response. Copyright (C) 2000 S. Karger AG, Basel.

AB - Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis. Using an established fixed dosing scheme for the administration of suramin in patients, a pilot study was conducted in patients with progressive, metastatic breast cancer. The primary objective of this trial is to define the effect of suramin on the angiogenic activity in individual patients using in vitro laboratory assays. The secondary objective was to assess the antitumor effect of suramin in a population of metastatic breast cancer patients. No objective tumor responses were observed in any of the 9 patients who received treatment with suramin, however 1 patient did maintain stable disease status. The strength of angiogenic activity present in patient samples was assessed by testing patient plasma in the capillary endothelial cell migration assay. Angiogenic activity followed over time was lowest in patients with the highest suramin concentrations and highest in patients with the lowest suramin concentrations. We conclude that it is feasible to continually monitor the activity of antiangiogenic agents in individual patients without relying on clinical tumor response. Copyright (C) 2000 S. Karger AG, Basel.

KW - Antiangiogenesis

KW - Breast cancer

KW - Suramin

UR - http://www.scopus.com/inward/record.url?scp=0034062773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034062773&partnerID=8YFLogxK

U2 - 10.1159/000012120

DO - 10.1159/000012120

M3 - Article

C2 - 10838499

AN - SCOPUS:0034062773

VL - 58

SP - 324

EP - 333

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 4

ER -